Ibalizumab-uiyk (Trogarzo)

Trogarzo (ibalizumab‑uiyk) is covered only for its FDA‑approved use — as part of combination antiretroviral therapy for heavily treatment‑experienced adults (≥18) with multidrug‑resistant HIV‑1 who are failing their current regimen; patients <18, monotherapy, and off‑label/compendial uses are not covered. Initial approval requires HIV RNA >1,000 copies/mL, documentation of heavy treatment experience (prior use of ≥10 antiretrovirals) and drug‑resistance testing confirming regimen failure; reauthorization is time‑limited (12 months) and requires maintained viral suppression to HIV RNA <200 copies/mL.

"Is at least 18 years old."

Sign up to see full coverage criteria, indications, and limitations.